BerGenBio Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
BerGenBio's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 66.5% per year.
Key information
-7.0%
Earnings growth rate
12.9%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -66.5% |
| Return on equity | -149.4% |
| Net Margin | -53,785.6% |
| Next Earnings Update | 29 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How BerGenBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -190 | 49 | 0 |
| 30 Sep 23 | 0 | -226 | 61 | 0 |
| 30 Jun 23 | 0 | -258 | 60 | 0 |
| 31 Mar 23 | 0 | -293 | 64 | 0 |
| 31 Dec 22 | 0 | -302 | 64 | 0 |
| 30 Sep 22 | 1 | -294 | 62 | 0 |
| 30 Jun 22 | 1 | -304 | 74 | 0 |
| 31 Mar 22 | 1 | -309 | 71 | 0 |
| 31 Dec 21 | 1 | -309 | 71 | 0 |
| 30 Sep 21 | 1 | -314 | 71 | 0 |
| 30 Jun 21 | 1 | -311 | 61 | 0 |
| 31 Mar 21 | 1 | -290 | 57 | 0 |
| 31 Dec 20 | 1 | -257 | 52 | 0 |
| 30 Sep 20 | 0 | -241 | 48 | 0 |
| 30 Jun 20 | 0 | -218 | 40 | 0 |
| 31 Mar 20 | 0 | -204 | 38 | 0 |
| 31 Dec 19 | 9 | -199 | 35 | 0 |
| 30 Sep 19 | 11 | -193 | 32 | 0 |
| 30 Jun 19 | 11 | -186 | 36 | 0 |
| 31 Mar 19 | 11 | -182 | 33 | 0 |
| 31 Dec 18 | 2 | -192 | 32 | 0 |
| 30 Sep 18 | 0 | -188 | 32 | 0 |
| 30 Jun 18 | 0 | -186 | 29 | 0 |
| 31 Mar 18 | 0 | -171 | 28 | 0 |
| 31 Dec 17 | 0 | -182 | 28 | 0 |
| 30 Sep 17 | 0 | -162 | 21 | 0 |
| 30 Jun 17 | 0 | -142 | 16 | 0 |
| 31 Mar 17 | 0 | -175 | 14 | 0 |
| 31 Dec 16 | 0 | -130 | 12 | 0 |
| 30 Sep 16 | 0 | -127 | 18 | 0 |
| 30 Jun 16 | 0 | -128 | 22 | 0 |
| 31 Mar 16 | 0 | -82 | 24 | 0 |
| 31 Dec 15 | 0 | -72 | 23 | 0 |
| 30 Sep 15 | 0 | -70 | 20 | 0 |
| 30 Jun 15 | 0 | -64 | 17 | 0 |
| 31 Mar 15 | 1 | -57 | 15 | 0 |
| 31 Dec 14 | 1 | -58 | 15 | 0 |
Quality Earnings: 0RU5 is currently unprofitable.
Growing Profit Margin: 0RU5 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RU5 is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare 0RU5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0RU5 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0RU5 has a negative Return on Equity (-149.36%), as it is currently unprofitable.